KENILWORTH, NJ & MIAMI – (COMMERCIAL THREAD) – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the presentation of previously announced Phase 2 interim results from two phase clinical trials 2/3 (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482 / EIDD-2801), an experimental oral antiviral therapy. The data were presented during the last clinical trial session at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The phase 3 portion of the global MOVe-OUT trial studying molnupiravir in outpatient adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. In addition, Merck plans to launch a clinical program to evaluate molnupiravir for post-exposure prophylaxis in the second half of 2021.
“Advancing potential antiviral treatments remains extremely important to address the devastating impact of COVID-19 globally, âsaid Dr. Roy Baynes, senior vice president and head of global clinical development, medical director from Merck Research Laboratories. “If successful, molnupiravir could help meet the urgent and continuing need for treatment. ”
“These data are promising and we are delighted to be able to present interim results from phase 2 of molnupiravir as we proceed to phase 3 of MOVe-OUT in outpatients, âsaid Wendy Holman, Managing Director of Ridgeback Biotherapeutics. . “There remains a great need for a range of solutions for the pandemic, and we hope that molnupiravir will play a role in helping patients. ”
For more information about our clinical trials, please visit https://merckcovidresearch.com/ or https://clinicaltrials.gov.
Molnupiravir (EIDD-2801 / MK-4482) is an experimental orally bioavailable form of a potent ribonucleoside analogue that inhibits the replication of several RNA viruses, including SARS-CoV-2, the causative agent of COVID -19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for the prophylaxis, treatment and prevention of transmission, as well as in SARS-CoV-1 and MERS. EIDD-2801 was invented by Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotech company 100% owned by Emory University and is developed by Merck & Co., Inc. in conjunction with Ridgeback Biotherapeutics. Since being authorized by Ridgeback, all funds used for the development of EIDD-2801 / MK-4482 have been provided by Wayne and Wendy Holman and Merck.
About Ridgeback Biotherapeutics
Based in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. Ridgeback Ebanga MarketsMT for the treatment of Ebola and has an advanced development pipeline that includes molnupiravir for the treatment of COVID-19. The development of molnupiravir is fully funded by Ridgeback Biotherapeutics and Merck & Co., Inc. All of Ridgeback Biotherapeutics LP’s equity comes from Wayne and Wendy Holman, who are committed to investing in and supporting life-saving medical technologies. The Ridgeback Biotherapeutics team is dedicated to finding solutions that save and change the lives of patients and diseases that need champions.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, providing drugs and vaccines for many of the world’s most difficult diseases as part of our mission to save and improve lives. We demonstrate our commitment to patients and the health of the population by increasing access to health care through broad policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company. in the world. For more information, visit www.merck.com and contact us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-looking statement by Merck & Co., Inc., Kenilworth, NJ, United States
This press release from Merck & Co., Inc., Kenilworth, NJ, United States (the âCompanyâ) includes âforward-looking statementsâ within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act. from 1995. These statements are based on the current beliefs and expectations of the management of the company and are subject to significant risks and uncertainties. There can be no assurance with respect to the products in the pipeline that the products will receive the necessary regulatory approvals or prove to be commercially successful.. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including fluctuations in interest rates and exchange rates; the impact of the global novel coronavirus disease (COVID-19) epidemic; the impact of pharmaceutical industry regulation and health care legislation in the United States and globally; global trends towards controlling health spending; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of patents and other corporate protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions.
The company does not undertake to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in forward-looking statements can be found in the company’s 2020 annual report on Form 10-K and other documents filed by the company with the Securities. and Exchange Commission (SEC) available from the SEC. Website (www.sec.gov).